Vision
About Doctor Haruhiko InufusaMessage from the CEO
TIMA TOKYO INC.
CEO Sho Tanaka
About Doctor Haruhiko Inufusa
Haruhiko Inufusa
- Doctor,M.D.
- Antioxidant Laboratory, Louis Pasteur Medical Research Center,Presidential Researcher
- Antioxidant Research Department,Joint Research Lecture,Gifu University Research Foundation Center,Distinguished Professor
- TIMA establishment Chief Researcher
- Japan Society for the Prevention of Cognitive Dysfunction,Certification Creation Committee,Executive Committee Member
- Director of Japan brain nutrition supplementary food association
url: https://www.youtube.com/channel/UCqLUacXBk84-VsGas0syFHQ
Company
Tokyo head office
Date of establishment |
June 1, 2015 (*The predecessor company was established on December 1, 2006) |
Representative | CEO Sho Tanaka |
Location |
・Tokyo head office ・Osaka Branch |
Capital | 21 million yen |
Major shareholders | TIMA establishment |
Business content | Production and sales of SPALIV |
Osaka Branch
Date of establishment |
June 21, 2019 |
Representative | CEO Sho Tanaka | Location |
・Tokyo head office ・Osaka Branch |
Capital | 8 million yen |
Major shareholders | TIMA establishment |
Business content | Production and sales of Oxicut, production and sales of Mtcontrol |
Research Office
Antiacidification Laboratory of Louis Pasteur Medical Research Center
〒606-8225 103-5 Tanaka Monzen-cho, Sakyo-ku, Kyoto City
https://antioxidantres.jp/
Joint Research Lecture Antioxidant Research Department
〒501-1194 Inside the building of the Faculty of Medicine, Gifu University, 1-1 Yanaido, Gifu City, Gifu Prefecture
https://www1.gifu-u.ac.jp/~lsrc/staff/staff_anti.html
TIMA establishment
Alte Churer Strasse 45 FL-9496 Balzers Liechtenstein
CEO Markus Count Matuschka de Greiffenclau
Chair Research Haruhiko Inufusa
Directors
Markus Count Matuschka de Greiffenclau
CEOSince 1990, he has provided investment and business consulting services to Skype and other companies. Since 2005, the TIMA establishment has been established for the purpose of donating medical research and served as the CEO.
Currently, centered on biotechnology, the company is engaged in various investment operations including “Lysando(http://www.lysando.com)”, a company that owns patents such as antimicrobial drugs that do not cause drug resistance.
Haruhiko Inufusa
Chief ResearcherBorn in Okayama Prefecture, graduated from the Faculty of Medicine of Kinki University with a doctor of medicine.
After that, he successively served as a professor in the Department of Clinical Medicine, Faculty of Medicine, Kinki University, a visiting professor at the European Institute of Telesurgery at the University of Strasbourg, and a visiting professor at the surgical classroom at the University of Barcelona, Spain. In December 2006, he founded SUPALIV INC. Founding of a company), since 2013, he has been a special professor in the Antioxidant Research Department of Gifu University. In 2020, he will serve as (concurrently) the CEO and researcher of the Antioxidant Research Office of the Louis Pasteur Medical Research Center.
Sho Tanaka
CEOBorn in Kyoto Prefecture, graduated from Chuo University.
After graduating from university, he started investing and managing education and human resources in Japan and Southeast Asian countries in 2007.
Since 2015, he has participated in the planning as an operating member of the company.
Yohei Tsukamoto
DirectorRaised in the Republic of South Africa and the UK, graduated from Kobe City University of Foreign Studies.
Established a system development company in 2011 after conducting domestic and foreign business development at Fujitsu Co., Ltd. and MISUMI Co., Ltd.
Since 2015, he has participated in the planning as an operating member of the company.
Development history
January 2001 | Establishment of a TIMA establishment (Liechtenstein) for the purpose of medical research and development |
June 2005 | At present, Markus Matuschka v.Greiffenclau takes office as Director General of the TIMA establishment (Liechtenstein) |
November 2006 | At present, Haruhiko Inufusa is appointed as the President and Researcher of TIMA establishment (Liechtenstein) |
November 2006 | Brookfield Medical Co., Ltd. (now TIMA TOKYO INC., SUPALIV INC.) was established for the purpose of research and development by the research team led by Haruhiko Inufusa. |
November 2010 | Launched “SUPALIV”, a nutritional supplement for alcohol metabolism |
September 2013 | Sales of “SUPALIV” started at FamilyMart nationwide |
November 2013 | Haruhiko Inufusa is appointed as a Distinguished Professor of the Antioxidant Research Department of Gifu University |
December 2017 | The cumulative sales of “SUPALIV” exceeded 3 million |
August 2019 | TIMA TOKYO INC. was established for the purpose of production and sales business on the occasion of the official launch of the nutritional supplement “Oxicut” (academic name: Twendee X), which was born from antioxidant research. |
November 2019 | The cumulative sales of “SUPALIV” exceeded 4 million units, and the Japanese Society for the Prevention of Cognitive Dysfunction recognized “Twendee X” as Grade A |
July 2020 | Launched the mitochondrial nutritional supplement “Mtcontrol” |
April 2021 | The cumulative sales of “SUPALIV” exceeded 5 million |
November 2023 | The cumulative sales of “SUPALIV” exceeded 6 million |